Atrial Fibrillation — Identification of Arrhythmias With One-time ECG
Citation(s)
al-Fahoum AS, Howitt I Combined wavelet transformation and radial basis neural networks for classifying life-threatening cardiac arrhythmias. Med Biol Eng Comput. 1999 Sep;37(5):566-73.
Amann A, Tratnig R, Unterkofler K Reliability of old and new ventricular fibrillation detection algorithms for automated external defibrillators. Biomed Eng Online. 2005 Oct 27;4:60.
Barro S, Ruiz R, Cabello D, Mira J Algorithmic sequential decision-making in the frequency domain for life threatening ventricular arrhythmias and imitative artefacts: a diagnostic system. J Biomed Eng. 1989 Jul;11(4):320-8.
Chen SW A two-stage discrimination of cardiac arrhythmias using a total least squares-based prony modeling algorithm. IEEE Trans Biomed Eng. 2000 Oct;47(10):1317-27.
Lake DE, Moorman JR Accurate estimation of entropy in very short physiological time series: the problem of atrial fibrillation detection in implanted ventricular devices. Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H319-25. doi: 10.1152/ajpheart.00561.2010. Epub 2010 Oct 29.
Lee J, Nam Y, McManus DD, Chon KH Time-varying coherence function for atrial fibrillation detection. IEEE Trans Biomed Eng. 2013 Oct;60(10):2783-93. doi: 10.1109/TBME.2013.2264721. Epub 2013 May 22.
Li C, Zheng C, Tai C Detection of ECG characteristic points using wavelet transforms. IEEE Trans Biomed Eng. 1995 Jan;42(1):21-8.
Lian J, Wang L, Muessig D A simple method to detect atrial fibrillation using RR intervals. Am J Cardiol. 2011 May 15;107(10):1494-7. doi: 10.1016/j.amjcard.2011.01.028. Epub 2011 Mar 17.
Thakor NV, Zhu YS, Pan KY Ventricular tachycardia and fibrillation detection by a sequential hypothesis testing algorithm. IEEE Trans Biomed Eng. 1990 Sep;37(9):837-43.
Zhang XS, Zhu YS, Thakor NV, Wang ZZ Detecting ventricular tachycardia and fibrillation by complexity measure. IEEE Trans Biomed Eng. 1999 May;46(5):548-55.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
